The first combined HepC drug is registered in the Russian Federation

The drug includes a combination of two antiviral drugs, glecaprevir and pibrentasvir.

According to the State Register of Medicinal Products, on 13 April AbbVie registered in the Russian Federation a combined pangenotypic HCV drug gleсaprevir/pibrentasvir under the trade name “Maviret”.

This drug is a pangenotypic, completely interferon-free regimen and includes a combination of two antiviral drugs, glecaprevir and pibrentasvir.

“Maviret” is taken orally, three pills once a day, for 8 weeks.

The drug glecaprevir/pibrentasvir is included in the latest HCV treatment guidelines by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD).
This combination is the first and only pangenotypic one-pill regimen registered in Russia.

Another pangenotypic interferon-free regimen, consisting of two separate drugs, sofosbuvir and daklatasvir, is available in the Russian market; the treatment duration is 12 weeks. The average weighted cost of treatment with sofosbuvir + daklatasvir is approximately RUR 900,000 per 12 weeks.

The price of the drug in Russia is still unknown. The cost of the drug in the US is about USD 13,200 per package, or USD 26,400 for an 8-week course of treatment.

Post Views: 1,930